# PHASE 5.2 FINAL SCIENTIFIC DECISION

============================================================
PHASE 5.2 FINAL SCIENTIFIC DECISION
============================================================

DIRECTION B STATUS:
RED

PRIMARY FINDING:
SimuPharm’s chromatographic resolution model is predominantly additive (main effects explain 97.75% of variance in wide screening and 99.85% in narrow operational space), exhibits trivial total parameter interactions (sum(ST - S1) = 0.0447 < 0.05), and its sensitivity rankings are dominated by structural implementation artifacts (an inverted Van Deemter curve and flat linear retention modifier) that can be fully captured by standard second-order response surface methodology (R2 = 0.9966) without providing any actionable chromatographic insight.

SCIENTIFIC NOVELTY:
The candidate research direction possesses no defensible scientific novelty because variance-based global sensitivity analysis (Sobol decomposition) of liquid chromatographic robustness surfaces has already been solved in the peer-reviewed literature on rigorous, non-linear retention models (Ruan et al., 2021; Lebrun et al., 2022), reducing this project to applying an off-the-shelf Python library (SALib) to an uncalibrated, simplified educational simulation script without wet-lab validation.

STRONGEST EVIDENCE:
• Total interaction variance across all parameters is strictly below the pre-registered 5% falsification threshold (sum(ST - S1) = 0.0447 in wide design space; 0.0016 in narrow operational space).
• A conventional second-order polynomial response surface (RSM) explains 99.66% of the variance on unseen test points (RMSE = 0.0265), proving that 14,000 Monte Carlo Sobol runs provide zero incremental information over a standard 30-run DoE.
• Parameter rankings from a simple 126-run OFAT sweep correlate perfectly with Sobol rankings (Spearman rho = 1.000), meaning OFAT missed no structural interactions.
• Forensic engine inspection confirmed that temperature sensitivity is identically zero (S1 = 0, ST = 0) because temperature is completely omitted from the physics engine code, disproving the Phase 5.1 hypothesis of a 0.28 T x %B interaction.
• Over 33.9% of the sampled global design space generates hydraulic backpressures exceeding the 400 bar limit of standard HPLC instrumentation (up to 4,668 bar).

STRONGEST WEAKNESS:
• The primary sensitivity driver (Flow Rate, S1 = 0.388) is driven by an unphysical model artifact where plate height H is dominated by longitudinal diffusion (B = 0.05, C = 2.5e-9, u_opt = 4,472 mL/min), causing resolution to increase monotonically with flow rate across the entire operational range.
• Neither NIST SRM 870 nor the Tanaka database provides multi-dimensional operational parameter variance, leaving the study with zero independent empirical anchoring.
• Peak tailing factor is generated purely by pseudo-random number draws (U(0, 0.3)), preventing any physical study of peak asymmetry or silanol interactions.

BIGGEST REVIEWER RISK:
Hostile peer reviewers at top analytical chemistry journals (Journal of Chromatography A, Analytica Chimica Acta) will immediately identify that the simulator's flow-rate vs. resolution relationship is inverted relative to physical chromatography, that temperature is non-functional, that unphysical 4,000-bar conditions were sampled without hydrodynamic constraints, and that a standard Box-Behnken DoE already captures 99.7% of the model's response surface, resulting in summary desk rejection for lack of physical validity, empirical data, and methodological necessity.

INDEPENDENT VALIDATION STATUS:
FAILED (Zero empirical multi-factor operational datasets exist within SimuPharm; neither NIST SRM 870 nor Tanaka can validate sensitivity surfaces).

GSA VS OFAT:
REDUNDANT (Spearman rank correlation rho = 1.000; OFAT identified the identical parameter hierarchy in 126 runs).

GSA VS DOE/RSM:
REDUNDANT (Standard 2nd-order response surface achieves test R2 = 0.9966 and RMSE = 0.0265, rendering global variance decomposition superfluous).

MODEL-ARTIFACT RISK:
HIGH (Flow sensitivity is dominated by an inverted Van Deemter curve; retention is governed by a flat linear modifier heuristic).

RANGE-DEPENDENCE:
HIGH (Interactions collapse from 4.47% in wide screening to 0.16% in narrow AQbD space, where Column Length dominates at 77.9%).

CONVERGENCE:
PASS (Point estimates converge within 0.15% at N = 1024, CI < 0.044, run time = 13.4 seconds).

PHYSICAL PLAUSIBILITY:
FAIL (33.98% of design space violates 400 bar HPLC pressure limit; maximum backpressure reaches 4,668 bar).

PUBLICATION POTENTIAL:
LOW (Estimated peer-review rejection probability > 95% in analytical chemistry journals).

RECOMMENDED JOURNAL:
NONE for Direction B. (Direction G is recommended for SoftwareX; Direction C is recommended for Journal of Pharmaceutical and Biomedical Analysis).

NEXT ACTION:
EXECUTE IMMEDIATE STRATEGIC PIVOT TO DIRECTION G (SoftwareX Scientific Software Paper on the SimuPharm Multi-Instrument Open Simulation Architecture) and DIRECTION C (Multimodal Orthogonal QC Identification).

KILL CONDITION:
KILL CONDITIONS 1, 4, 5, 6, 7, AND 10 ACTIVATED (Trivial Interactions < 0.05, Domain Implausibility > 30%, DoE Redundancy R2 > 0.98, Dominance of Model Artifacts, Lack of Empirical Anchoring, and Mere Implementation Paper).

FINAL GOVERNANCE:
KILL
